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Abstract 
 
Patterns of HIV, TB, and non-communicable disease multi-morbidity in an informal peri-
urban setting in Cape Town, South Africa 
Tolu Oni; MMed (Public Health) 
University of Cape Town 
 
Supervisor:  David Coetzee 
 
BACKGROUND 
Many low and middle-income countries are experiencing colliding epidemics of chronic infectious 
(ID) and non-communicable diseases (NCD). As a result, the prevalence of multiple morbidities 
(MM) is rising. 
METHODS 
We conducted a retrospective study to describe the epidemiology of MM in a primary care clinic in 
Khayelitsha, an informal township in Cape Town. Adults with at least one of HIV, tuberculosis 
(TB), diabetes (T2DM), and hypertension (HPT) were identified between Sept 2012-May 2013 on 
electronic databases. Using unique patient identifiers, drugs prescribed across all facilities in the 
province were linked to each patient and each drug class assigned a condition. 
RESULTS 
These 4 diseases accounted for 45% of all prescription visits. Among 14364 chronic disease 
patients, HPT was the most common morbidity (65%). 22.6% of patients had MM, with an 
increasing prevalence with age, and a high prevalence among younger antiretroviral therapy (ART) 
patients (26% in 18-35yr and 30% in 36-45 year age groups). HPT and T2DM prevalence was 
higher among younger ART patients with MM compared to those not on ART. Of note, 37% of TB 
MM patients were also on treatment for HPT and 12% were on treatment for T2DM respectively, 
and 86% of T2DM patients were on HPT treatment.  
 
CONCLUSION 
We highlight the co-existence of multiple ID and NCD. This presents both challenges (increasing 
complexity and the impact on health services, providers and patients), and opportunities for chronic 
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diseases screening in a population linked to care. It also necessitates re-thinking of models of health 
care delivery and calls for policy interventions that integrate and coordinate management of co-
morbid chronic diseases. 
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PART A: PROTOCOL  
A.1 INTRODUCTION 
A.1.1 Background  
The concept of multi-morbidity (MM), defined as the co-existence of more than one chronic 
condition in one person, is well recognized, usually within the context of older age [1]. Patients with 
MM have increased utilization of health care, reduced quality of life and poorer health outcomes [2-
4]. A recent systematic review of MM patterns described a non-random pattern of MM for which 
common pathophysiological mechanisms underlie each disease constellation [1]. However all 
studies in this review were conducted in high-income settings, predominantly in older age 
populations, and included only non-communicable diseases (NCD). In low- and middle-income 
countries (LMIC), with burgeoning urbanisation, not only is the prevalence of NCD increasing, it is 
occurring alongside chronic infectious diseases. Thus patterns of MM may differ.  
South Africa is the most urbanised country in sub-Saharan Africa with 62% of the country’s 
population living in cities [1, 5]. The rapid and unplanned nature of this demographic shift affects 
life choices and opportunities; contributing to an epidemiological transition with an increase in 
unhealthy dietary patterns, a decrease in physical activity and a rising NCD burden [2-4, 6, 7]. South 
Africa has the highest burden of hypertension (HPT) in the >50years old population and among the 
highest type 2 diabetes mellitus (T2DM) prevalence in sub-Saharan Africa [1, 8]; and this is 
predicted to increase further over the next few decades. Against this background, the burden of HIV 
and TB remain high. Effective antiretroviral therapy (ART), in widespread use in South Africa since 
2005/6, has resulted in increasing survival and ageing among HIV-infected persons and an 
accompanying rise in NCD co-morbidities in this sub-group [9, 10]. Furthermore, the premature 
ageing effect of HIV will likely further contribute to multiple morbidities in the population [11], at 
younger ages than described in low HIV-burden settings. The morbidity and mortality rates for 
NCD, HIV and TB in South Africa disproportionately affects poor people with the NCD burden 
fuelled by a high prevalence of obesity, which affects 40% of the adult female population [7]. 
However, when considering which strategies to implement and which will have the greatest impact, 
it is important to consider the degree of co-occurrence in the population, the strength of association 
and the interaction between prevalent diseases. Our literature review focuses on the interactions 
between the most prevalent infectious diseases (ID) and NCD in LMIC. 
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A.1.2 Problem statement  
Given the extent of overlap and interactions between these established and emerging epidemics, a 
better understanding of the patterns of chronic infectious and non-communicable disease MM in 
LMIC is therefore required to develop strategies to prevent and better manage these co-existing and 
interacting conditions. We aim to use routine data from a public health programme to explore the 
distribution of chronic diseases and patterns of HIV, TB, and NCD MM in adults who have received 
care and treatment in a public clinic. 
A.1.3 Research question 
 What is the prevalence and pattern of MM among patients receiving treatment for HIV, TB, 
T2DM or HPT? 
 Does the pattern of MM differ across age groups and sex? 
 Does the pattern of MM among patients receiving ART differ compared to patients not on 
ART? 
A.1.4 Research justification 
The burden of NCD is rising, particularly in LMIC undergoing rapid epidemiological transition. In 
many countries, including South Africa, this is occurring against a background of infectious chronic 
disease epidemics, especially HIV and TB. In South Africa, most HIV and NCD patients are 
managed at the primary care level in vertical programs. However, these colliding epidemics have 
highlighted the inadequacies of the existing system and more integrated management of commonly 
co-occurring is required. However, there is a paucity of data on the burden and patterns of MM 
among patients with chronic diseases in high HIV/TB burden settings. 
A.1.5 Objectives 
 To describe the baseline characteristics of patients receiving treatment for at least one of 
HIV, TB, T2DM or HPT 
 To measure the prevalence of MM among chronic disease patients, stratified by age and sex 
 To evaluate the pattern of MM among chronic disease patients 
 To compare the pattern of MM among patients receiving ART and those not on ART? 
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A.1.6 Summary of literature review  
We reviewed interactions between ID and NCD. There are extensive further examples of 
interactions between infectious and NCD; and these interactions are complex, often mediated by 
shared risk factors. However the purpose of this review is not to be an exhaustive archive of all 
interactions, but to focus on interactions associated with infectious diseases with the highest global 
burden. As such, the review will focus on HIV, TB, and malaria; and the interactions with the most 
prevalent NCD in LMIC. Within each section, we present available evidence on the prevalence of 
co-existence of diseases and risk factors, describe the strength of association between the diseases, 
and the impact of co-morbidity on clinical manifestation, diagnosis and prognosis of either 
condition. Summarised for the protocol are excerpts from the review related to TB and HIV; and 
their interaction with diabetes, cardiometabolic disease and chronic obstructive pulmonary disease 
(COPD). 
A.1.6.1 Tuberculosis  
TB remains a leading cause of death globally, with an estimated 8.8 million new cases reported 
every year, threatening the goal of global TB elimination by year 2050 [12]. Tackling this challenge 
will require not only improvements in diagnostic and treatment services, but identification and 
reduction of risk factors that increase TB susceptibility. Diseases and risk factors that impair 
immune function, such as malnutrition, alcoholism or HIV co-infection, can increase the likelihood 
of infection or reactivation of latent TB.  
A.1.6.1.1 Tuberculosis and T2DM 
Increasing evidence suggests that T2DM is a significant risk factor for TB and this emerging 
epidemic could therefore threaten TB control. In a recent systematic review, the relative risk for TB 
in diabetic patients was 3.1 in two cohort studies, with odds ratios that ranged from 1.16 to 7.83 in 
case–control studies [13]. The strength of this link was influenced by geographic/ethnic differences, 
and the relative risk was higher in younger than older adults; in India, it is estimated that 15% of 
smear positive pulmonary TB cases are attributable to DM [14]. However, these studies had a 
number of limitations. In particular, very few were carried out in low-income countries, with no sub-
Saharan African studies included, raising uncertainty about the strength of T2DM-TB association 
and benefit of bi-directional screening for T2DM and TB in these settings (where not only is the 
prevalence of TB and HIV high, but also where the burden of T2DM is predicted to increase most 
rapidly) [15]. Nonetheless the World Health Organization (WHO) issued provisional 
 13 
recommendations that all TB patients be screened for T2DM and vice versa, while noting that 
evidence for the effectiveness and cost-effectiveness of integrated approaches is poor [16]. 
TB/T2DM co-morbidity influences the diagnostic accuracy of established algorithms for either 
condition and there is a lack of knowledge of, or practical guidance on, the most appropriate 
screening methods, further impeding implementation of the WHO guidelines. WHO approved 
approaches to the diagnosis of T2DM include the measurement of fasting glucose, an oral glucose 
tolerance test (which assesses blood glucose level after a standard glucose load), and most recently 
glycated haemoglobin (HbA1c), which reflects average blood glucose level over the preceding few 
weeks [17, 18]. It is known that acute illness, such as TB, can result in a transient stress induced 
hyperglycaemia, thus influencing the diagnostic reliability of these tests, especially the first two. 
HbA1c may be more reliable in TB given that it reflects average glucose levels over the preceding 
month or so. However, good data on the performance of diagnostic tests for T2DM in TB are 
lacking. Also lacking are good data on the potential importance in people with TB of levels of 
hyperglycaemia below the T2DM threshold, referred to as intermittent hyperglycaemia or pre-
diabetes [17]. There are also presently insufficient data on which to base TB screening guidelines 
for diabetic patients. 
In spite of these challenges, the importance of bidirectional screening for TB and T2DM is 
underscored by the impact of T2DM on TB outcomes and vice versa. The co-existence of T2DM in 
TB patients is associated with a longer duration of TB symptoms, more severe TB disease and 
poorer TB outcomes [19-24], with greater mortality reported among TB patients with T2DM 
compared to those without T2DM [25].  There is also some evidence to suggest further increased TB 
risk in persons with poor glycaemic control [26, 27]. TB can aggravate T2DM by worsening 
glycaemic control complicating clinical management [28].  It has also been proposed that the 
metabolism of rifampicin could be affected by T2DM, making it less effective and predisposing 
patients to the acquisition of drug resistance [20, 29]. 
There is a paucity of data on whether T2DM is associated with a high prevalence of subclinical TB 
among patients attending diabetic clinics, as observed in HIV co-infected persons [30]. This has 
major importance when considering TB screening strategies - as symptom-based screening will not 
detect subclinical disease, with potential for amplification of transmission within diabetic clinics and 
also potentially serious consequences of false-negative TB screening. 
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A.1.6.1.2 Tuberculosis and COPD 
Due to the similarity between TB and COPD symptoms, there is potential for delayed diagnosis of 
TB further impacting on outcomes. Persons with COPD have a two to three-fold higher risk of 
developing TB [31] and a two-fold increased mortality than non-COPD patients [32]. The increased 
risk of TB associated with COPD is often attributed to smoking [33]. But studies have also found an 
association between oral corticosteroid use in COPD patients and TB risk [31]. A systematic review 
confirmed that although this association is independent of smoking [34], the risk of COPD is further 
increased by tobacco smoking and low socioeconomic status, common risk factors for both COPD 
and TB. 
The histopathological changes that occur in the lungs of TB patients can result in anatomical 
changes associated with both obstructive and restrictive patterns of impaired lung function of 
varying severity, which can persist after successful completion of TB treatment [35]. The prevalence 
of COPD after TB treatment completion varies from 28% to 68% [36], and is further increased in 
persons with multiple episodes of TB [37]. Childhood studies have also demonstrated this 
association, due to prolonged bronchial obstruction by enlarged lymph nodes during TB disease 
[38]. In LMIC, alongside a concomitant rise in the prevalence of tobacco smoking, TB is an 
important contributor to poor quality of life and DALYs lost due to COPD [39]. A study in South 
Africa reported that the strongest predictor of chronic bronchitis was a history of TB [40]. Early 
identification and management of chronic lung impairment is therefore crucial to minimizing the 
long-term negative impact of TB.  
A.1.6.2 HIV  
Globally, HIV is the 5th and 6th leading cause of DALYs lost and mortality, respectively [41, 42]. In 
LMIC, particularly in sub-Saharan Africa, HIV ranks even higher. However, unlike the NCD trend, 
there are promising signs that the HIV pandemic is abating in high burden settings, with declining 
incidence and mortality rates [43]. Nonetheless, the rising NCD morbidity and mortality rates 
alongside an established HIV epidemic makes it crucial to better understand the interactions that 
exist with emerging non-communicable diseases and disease precursors. These interactions can 
either be related to HIV infection directly or as a side effect of ART. LMIC bear a disproportionate 
burden of the HIV pandemic. Despite a roll out of ART, this treatment does not fully restore health 
in all individuals; HIV-infected adults on treatment have higher than expected risk of several non-
AIDS disorders, including cardiovascular disease, kidney disease, liver disease, malignancy, 
dementia, neuropathies, and musculoskeletal disorders. HIV has also been identified as an 
independent risk factor for stroke in urban and rural Tanzania [44], although there is a paucity of 
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data on the nature and extent of this interaction in other LMIC. 
A.1.6.2.1 HIV and metabolic syndrome  
Metabolic syndrome includes disturbances in glucose, lipid metabolism and insulin resistance and is 
a significant risk factor for cardiovascular disease and T2DM.  
-Insulin resistance 
There is evidence that HIV infection is associated with abnormal glucose metabolism and 
hyperglycaemia independent of ART. The association of HIV infection and T2DM is poorly 
understood and there is conflicting evidence of this association, independent of ART [45, 46]. The 
use of ART containing protease inhibitors (PI) and nucleoside reverse transcriptase inhibitors has 
been associated with insulin resistance [47, 48]. A Cape Town survey of HIV-infected persons on 
ART reported a 21.9% prevalence of newly detected hyperglycaemia and a significant association 
with the drug efavirenz [49]. This could contribute to the T2DM epidemic as patients receive ART 
for longer periods.  
-Dyslipidaemia/lipoatrophy 
HIV-related hyperlipidaemia (particularly hypertriglyceridaemia), independent of ART has been 
described [50]. However, the use of ART is also associated with dyslipidaemia, peripheral wasting 
and central fat accumulation. In particular, PI and non-nucleoside reverse transcriptase inhibitors 
(NNRTI)-based regimens have been associated with dyslipidaemia and atrophy. PI drugs are 
particularly associated with dyslipidaemia, a known risk factor for cardiovascular complications [51, 
52]; patients with baseline elevated lipid levels have the greatest risk of developing hyperlipidaemia, 
especially hypertriglyceridaemia [51]. A study conducted in South Africa reported and association 
between ART use and increased central fact and reduced peripheral fat. This was partially improved 
by switching from an NNRTI-regimen to a PI-based regimen [53].  
A.1.6.2.2 HIV and the heart 
The burden of cardiovascular disorders is increasing in LMIC. The most commonly reported cardiac 
manifestation in HIV is pericardial disease; often due to TB [54]. HIV-related cardiomyopathy is 
also common with prevalence ranging between 18-43% in LMIC [55, 56], as is pulmonary 
hypertension. The prognosis of these conditions has historically been poor [57, 58]. Evidence from 
Africa on the prevalence of echocardiographic abnormalities in asymptomatic HIV-infected persons 
is limited although documented in other regions [59, 60]. There is also an increased risk of 
myocardial infarction in HIV-infected patients on ART, particularly in patients with metabolic 
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syndrome [61]. 
A.1.6.2.3 HIV and Chronic Kidney Disease 
Chronic kidney disease (CKD) is an important cause of morbidity and mortality in HIV-infected 
persons; including HIV-associated nephropathy (HIVAN) and membranoproliferative 
glomerulonephritis, particularly in the presence of hepatitis C co-infection [62]. The risk of CKD is 
further increased in the presence of other risk factors including older age, hypertension, T2DM, and 
black ethnicity [63]. This is of particular concern as the prevalence of T2DM and HPT is rising 
within the same population with a high HIV prevalence. Although the incidence of CKD has been 
remarkably altered by widespread ART access, some ART regimens are associated with incident 
acute or chronic kidney disease; particularly with indinavir and tenofovir [64]. Studies of HIV-
infected patients on ART in Taiwan and Vietnam reported a 7% prevalence of CKD, with older age, 
lower body weight and tenofovir use being independently associated with CKD [65, 66]. However, 
the benefits of tenofovir are considered to outweigh the nephrotoxic side effects and tenofovir is 
recommended as the first line ART regimen. The prevalence of proteinuria at baseline, with or 
without a raised serum creatinine level, is reported to be a sensitive predictor of development of 
CKD [67], suggesting that this should be measured in all HIV-infected patients at diagnosis and at 
initiation of ART.  
A.2 METHODS  
A.2.1 Study design 
A retrospective study, reviewing chronic medication prescriptions over a 9-month period in one 
clinic. 
A.2.2 Study setting 
We will conduct this study in Michael Mapongwana clinic, a primary care health facility in 
Khayelitsha, an informal township near Cape Town with a population of >500 000 predominantly 
black Africans.  
A.2.3 Data sources 
Data on treatment prescriptions will be extracted from two routine electronic databases. Patients 
who are considered stable on chronic disease medication receive their monthly prescriptions through 
the Chronic Disease Dispensing unit (CDU), an outsourced centralised unit that collects 
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prescriptions for stable chronic patients from health facilities, dispenses the medicines, and returns 
them to the facilities which the patients attend, packaged in tamper-proof parcels. A record of 
medicines dispensed is kept on a database that is sent to the Western Cape Department of Health 
Data Repository on a monthly basis. The second database to be used is the electronic prescription 
system that manages pharmacy prescriptions electronically. This system has been in use across 
secondary and tertiary-level hospitals in the Western Cape province for >10 years and enables 
pharmacy records linked to an individual patient to be accessible across hospitals. Roll out of this 
system in primary care clinics began in September 2012 in Michael Mapongwana clinic in 
Khayelitsha. This database captures chronic disease patients not receiving medicines through the 
CDU. Every patient accessing health care in the public clinics and hospitals is ascribed a unique 
patient master index (PMI) that serves to link prescriptions across different databases and health 
care facilities in the province. 
A.2.4 Population and sampling strategy 
Persons prescribed medicines for at least one of the four most prevalent chronic diseases (HIV, TB, 
T2DM, HPT) will be identified from the electronic pharmacy and CDU databases over a 9-month 
period to capture 6-monthly prescriptions over a 9-month period from the electronic pharmacy 
databases. The anonymised dataset to be extracted includes age, sex, and medications prescribed at 
all consultations over the study period. Using the PMI, medicines, prescribed across all health 
facilities in the province will be linked to each patient. Each drug class will be assigned a condition 
based on South African prescription guidelines: HPT defined as a prescription of at least one of 
hydrochlorthiazide, enalapril, or amlodipine; T2DM defined as a prescription of metformin, 
gliclazide, glibenclamide, or insulin; HIV/ART defined as prescription of ART; TB defined as 
prescription of rifampicin, isoniazid, or pyrazinamide. MM will be defined as receiving medication 
for two or more of the 4 morbidities measured. Of note, due to the data source used, the study is 
unable to distinguish between HIV infected patients not on ART and HIV-uninfected persons. The 
HIV/ART group therefore refers only to HIV-infected persons receiving ART; and the comparison 
group is HIV status unknown (HIV-uninfected and HIV-infected not on ART) 
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A.2.5 Data collection  
A.2.5.1 Study variables 
Variable Definition Category 
Age Age in years (18 and older) Continuous 
Gender Male or female Categorical 
HIV/ART Prescribed antiretroviral therapy Categorical 
TB Prescribed rifampicin, isoniazid, 
pyrazinamide, or ethambutol 
Categorical 
T2DM  Prescribed insulin metformin, gliclazide, or  
glibenclamide 
Categorical 
HPT  Prescribed hydrochlorthiazide, enalapril, or 
amlodipine 
Categorical 
Multi-morbidity  The presence of 2 or more of the selected 
chronic diseases 
Categorical 
 
A.2.6 Statistical analysis  
Descriptive analyses will be represented using percentages, frequencies, and tabulation. Age 
categories 18-35, 35-45, 46-55, >55 will be used to explore the age-distribution of chronic diseases 
and MM; stratified by sex using the λ2 test. The prevalence of MM will also be calculated stratified 
by HIV/ART status across the different age groups. Co-morbidity patterns across the individual 
chronic diseases will be examined. The λ2 test will be used to measure differences in the prevalence 
of chronic diseases and MM. Significance testing will be done using 2-sided p-values and 95% 
confidence intervals. All data will be analysed using STATA 12.0 (StataCorp, College Station, TX, 
USA). 
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A.3 ETHICAL CONSIDERATIONS 
A.3.1 Harm 
Individual patient data are anonymised with patients identified solely by unique patient identifier 
codes. Therefore no harm will be caused to patients. 
A.3.2 Benefit 
While individual patients may not directly benefit from the project, a greater understanding of the 
pattern of chronic disease co-morbidity will inform decisions on how best to deliver chronic health 
care at the primary care level. 
A.3.3 Confidentiality 
Due to the sensitive nature of the data to be collected, maintaining the confidentiality of clinical 
information is of high priority. Measures to ensure confidentiality will include:  
a) Computerized data will identify individuals only by code.  
b) All reports and publications will refer only to anonymous or pooled data. 
A.4 BUDGET 
There is no budget allocated to this study, as there is no primary data collection or patient 
recruitment required.  
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PART B: LITERATURE REVIEW  
B.1 OBJECTIVES 
A good understanding of the burden of disease and risk factors is important because in addition to 
these conditions co-existing, diseases, disease precursors, and risk factors can also interact 
influencing host susceptibility (e.g. T2DM increases the risk of TB, ART can increase the risk of 
dysglycaemia), clinical manifestation, and disease prognosis (e.g. chronic kidney disease (CKD) and 
the co-existence of HIV and HPT), further impacting on population health. These interactions could 
potentially impede strategies in place to improve health and reduce poverty. Whilst acknowledging a 
wide range of infectious and NCD, the rest of this review will focus on diseases, disease-precursors 
and risk factors that have a high prevalence in LMIC. In particular we will focus on those conditions 
where interactions between them are known to be, or thought likely to be, of public health 
importance.  
B.2 INTRODUCTION  
The broad classification of diseases into communicable (infectious) and non-communicable 
diseases is deeply ingrained. However, this classification may be unhelpful for setting public health 
priorities, particularly in low and middle-income countries (LMIC) 1. For example, using data from 
Tanzania it has been shown that classifying diseases as acute versus (vs.) chronic, rather than 
communicable vs. non-communicable, dramatically changes the distribution of disease burden 2. 
The ‘acute vs. chronic’ approach to disease classification demonstrated the equal burden of 
diseases requiring chronic care vs. acute care even though the vast majority of the disease burden 
was classified as ‘communicable’ 2.  
 
In this critical review we illustrate the co-existence of diseases in these categories and their 
interactions that lead to increased morbidity. We focus on interactions likely to be of public health 
importance in LMIC, but also in marginalized populations in high-income countries. We argue that 
public health approaches to the prevention and control of these diseases must be fully informed by 
these interactions and move beyond the communicable/non-communicable divide. 
 
The context of the epidemiologic transition 
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On a superficial level the original concept of the epidemiologic transition3 can appear to provide a 
clear rationale for the communicable/non-communicable divide. The transition is seen to consist of 
falling mortality from communicable diseases, particularly in infancy and childhood, followed by an 
increasing predominance of deaths from ‘man-made degenerative diseases’ 3.  However, this was 
always a limited interpretation. Re-analysis of historical data from Sweden has shown how patterns 
of falling death rates varied greatly between different regions, with some continuing to experience 
high rates of communicable disease mortality while this fell dramatically in others 4.  It is clear that 
over the past 50 years many low and middle-income countries have seen emerging epidemics of 
chronic non-communicable diseases while continuing to experience high rates of communicable 
disease 5.  
 
Table 1 illustrates the heterogeneity of conditions contributing to the Burden of Disease in 12 low 
and middle-income regions. It highlights the significant contribution of NCD to Disability-adjusted 
Life Years lost in most LMIC. In 8 of the regions, including Southern Africa, North Africa/Middle 
East and Latin America, both major communicable diseases and non-communicable diseases 
(NCD) are within the top ten conditions contributing to the Burden of Disease. This highlights the 
fact that a continued approach to public health along the dichotomous parallel lines of 
communicable and non-communicable diseases is increasingly redundant in these settings. 
Interactions between communicable and NCD are complex and often mediated by shared risk 
factors (Figure 1). This review aims to provide an up to date account of interactions between NCD 
and communicable diseases likely to be of public health importance to LMIC, as well as 
marginalized populations in high-income settings.  
 
Table B.1: Rankings of diseases according to their contribution to Disability Adjusted Life Years 
(DALYs) in different global regions (adapted from the Global Burden of Disease 2010 report). The 
shaded areas indicate DALYs lost due to NCD; the numbers in bold represent regions where NCD 
are in the region’s top ten contributors to DALYs lost.  
Disease 
Rankings 
Sout
hern 
Afric
a 
East 
Africa 
Central 
Africa 
West 
Africa 
N. Africa/ 
Middle 
East 
Southern 
Latin 
America 
Tropical 
Latin 
America 
Central 
Latin 
America 
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Asia 
   East Asia Central 
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ic heart 
disease 
14 21 19 20 1 1 1 2 3 4 2 1 
Lower 
respirato
ry 
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2 3 4 2 5 6 7 6 4 1 15 2 
Cerebro
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7 16 14 16 4 3 4 11 1 12 1 3 
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disease 
Diarrhoe
al 
disease 
3 4 2 3 11 44 26 14 8 3 49 18 
HIV / 
AIDS  
1 1 5 4 58 34 12 13 13 17 38 31 
Malaria 20 2 1 1 66 166 145 154 22 44 169 162 
COPD 9 20 20 22 13 7 10 16 9 5 3 11 
Major 
Depressi
ve 
disorder 
10 13 17 19 3 4 6 5 6 14 8 6 
Tubercul
osis 
4 7 7 12 33 65 46 44 2 8 37 15 
Diabetes 8 29 28 26 9 9 8 3 10 16 10 12 
 
 
Figure B.1: Interaction between TB, Malaria, and HIV; risk factors/disease precursors; and NCD. Key: COPD Chronic 
Obstructive Pulmonary Disease  
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B.3 METHODS 
The literature search was carried out between October 2013 - December 2014 and included 
literature published until December 2014. Our aim was to conduct a ‘critical review’ 6 . Unlike a 
systematic review, this does not aim at a comprehensive assessment of original research but rather 
seeks to identify the conceptual contribution of existing literature to the field of study 6. We 
searched for literature (English language) using the PubMed and EMBASE databases and the 
following combinations terms (as MESH and key words): [HIV OR tuberculosis OR malaria] AND 
[diabetes mellitus OR chronic obstructive pulmonary disease OR chronic kidney disease OR 
cardiovascular disease OR cardiomyopathy OR metabolic syndrome OR neurocognitive disease 
OR dementia OR epilepsy]. From the 24864 articles identified by this search strategy, we honed 
down on original research and review articles with titles and abstracts that were clearly pertinent to 
co-morbidity and interactions between one or more of the three communicable diseases and NCD. 
Articles were selected to ensure comprehensive representation of interactions reported in the 
literature. Both authors identified and reviewed papers and 80 articles were eventually included in 
the review. Of note, there was a lot of information about the NCD and TB or HIV interactions but far 
fewer studies on malaria and NCD. 
B.4 RESULTS 
B.4.1 Tuberculosis  
As table 1 shows, TB remains a leading cause of disability-adjusted-life-years in many regions of 
the world, particularly in poor populations in low and middle income countries. In 2012 it is 
estimated that there were 8.6 million new cases and 1.3 million deaths from TB 7. TB is preventable 
and curable, and therefore the goal of much lower incidence and mortality is appropriate 8. The 
2014 the World Health Assembly adopted ambitious new targets for TB: a 90% reduction in 
incidence and a 95% reduction in the number of deaths between 2015 and 2035 9. Achieving a 
90% reduction in incidence by 2035 will require a marked improvement in the rate of decline, from 
around 2% per year at present, to 10% per year by 2025 8. Achieving a 95% decrease in mortality 
will require more than halving the case fatality from 15% to 6.5% by 2025 8. Tackling this challenge 
will require improvements in diagnostic and treatment services and identification and reduction of 
risk factors that increase TB susceptibility. Diseases and risk factors that impair immune function, 
such as malnutrition, alcoholism or HIV co-infection, can increase the likelihood of infection or 
reactivation of latent TB. A study of the effect of multiple exposures to these risk factors reported 
that tobacco use, alcohol, type 2 diabetes mellitus (T2DM) and low body mass index (BMI) were 
significant individual risk factors and associated with triple or quadruple the risk of TB with multiple 
exposures 10. 
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B.4.1.1 Tuberculosis and Diabetes 
T2DM is a risk factor for TB. Two systematic reviews have demonstrated that T2DM increases the 
risk of incident TB by around three fold 11,12. Together these reviews included 15 studies, the vast 
majority of which were from high income countries. Since they were published more data have 
accumulated from low and middle income settings, essentially confirming the increased risk of TB 
in people with diabetes 13. In a case control study from Tanzania, for example, diabetes was 
associated with four fold increased risk of TB in HIV negative, but not positive, patients 14. Because 
diabetes is common (affecting 8.3% of the global adult population) the number of cases of TB 
attributable to diabetes is large. Globally, for example, diabetes is estimated to account for 15% of 
all adult cases of TB. Even in Africa, where diabetes prevalence in adults is estimated to be 5% 
(the lowest of all regions), and HIV is a major contributor to TB incidence, diabetes is still thought to 
account for almost 1 in 10 adult cases 8.  
In addition to increasing the risk of incident TB, diabetes is also a risk factor for poorer TB 
outcomes. A systematic review and meta-analysis found that the risk of death during TB treatment 
was almost twice as high in those with diabetes compared to those without, and relapse following 
treatment almost four times as high 15.  
These interactions between diabetes and TB have implications for achieving the 2035 WHO targets 
for TB incidence and mortality 9. Diabetes prevalence is expected to continue to increase over the 
coming decades, especially in LMIC 16.  Conservative estimates suggest that it will increase to 
around 10% globally in adults in 2035 16 and the results of modelling suggest that this would offset 
the present downward trend in incidence by around 3% 8. A less conservative estimate of the 
increase in diabetes prevalence, suggests that it will be 13% in 2035 and this would offset the 
decline in TB incidence by 8% 8.  
The strong association between TB and diabetes, and the poorer health outcomes associated with 
their co-existence, naturally leads to the question of whether patients with one condition should be 
screened for the other. The latest WHO strategy 9 recommends screening people with diabetes for 
active TB in settings with a high TB burden, such as where the TB incidence is 100/100,000/yr or 
more. The type of screening will depend on resources. A practical approach described in China and 
India is to screen all people with diabetes on each clinic visit with a symptom-based questionnaire 
with referral for further investigations for those who are positive 8. The WHO strategy also 
recommends that all people with TB are screened for diabetes, with referral for diabetes diagnosis 
and management for those who are positive 9.      
It is clear that diabetes and TB are intimately related. However, there remain many unanswered 
questions as to the most effective approaches to minimizing the morbidity and mortality from this 
interaction. These were summarized in a recent review 13, and include the following: 
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 What is the effect of glycaemic control on new TB infection, active TB and TB treatment 
outcomes, and what are the most effective approaches to achieving glycaemic control in 
people with TB? 
 What are the most feasible and valid approaches to screening for diabetes in patients with 
TB (noting that inflammation from TB infection may cause a transitory hyperglycaemic 
response)? 
 What models of health care delivery can deliver sustainable, integrated and cost-effective 
care for diabetes and TB in LMIC?  
 Is screening and prophylactic treatment of latent TB infection indicated in people with 
diabetes? 
A significant contribution to answering some of the questions on the diagnosis of diabetes in TB, 
the role of glycaemic control on TB outcomes, and the best way to deliver care, is being made by 
the TANDEM study 17, which began in 2013. This is a study working in four endemic TB countries 
that are experiencing rapid rises in diabetes prevalence (Romania, Peru, South Africa and 
Indonesia) and supported by researchers in Germany, UK and the Netherlands.  
 
B.4.1.2 Tuberculosis and Chronic Obstructive Pulmonary Disease 
Figure 1 shows the bi-directional nature of the interaction between TB and Chronic Obstructive 
Pulmonary Disease (COPD). Due to the similarity between TB and COPD symptoms, there is 
potential for missing the diagnosis of one when they co-exist. Persons with COPD have been found 
in one study to have a two to three-fold higher risk of developing TB 18, and a two-fold increased 
mortality compared to non-COPD patients 19. The increased risk of TB associated with COPD is 
often attributed to smoking 20. However, studies have also found an association between oral 
corticosteroid use in COPD patients and TB risk 18. A systematic review confirmed that although 
this association is independent of smoking 21, the risk of COPD is further increased by tobacco 
smoking and low socioeconomic status, common risk factors for both COPD and TB. 
 
The histopathological changes that occur in the lungs of TB patients can result in anatomical 
changes associated with both obstructive and restrictive patterns of impaired lung function of 
varying severity, which can persist after successful completion of TB treatment 22. The prevalence 
of COPD after TB treatment completion varies from 28% to 68% 23, and is further increased in 
persons with multiple episodes of TB 24. Childhood studies have also demonstrated this 
association, due to prolonged bronchial obstruction by enlarged lymph nodes during TB disease 25. 
In LMIC, alongside a concomitant rise in the prevalence of tobacco smoking, TB is an important 
contributor to poor quality of life and disability-adjusted life years (DALYs) lost due to COPD 26. A 
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study in South Africa reported that the strongest predictor of chronic bronchitis was a history of TB 
27. Early identification and management of chronic lung impairment is therefore crucial to minimizing 
the long-term negative impact of TB.  
B.4.1.3 Tuberculosis and Chronic Kidney Disease 
The prevalence of chronic kidney disease (CKD) is increasing, and it is estimated that 70% of 
patients with end stage renal disease will reside in LMIC by 2030 28. This has significant 
implications on infrastructural and financial resources. The most common causes of CKD in LMIC 
are chronic glomerulonephritis and interstitial nephritis due to infections including tuberculosis 28. 
Conversely CKD patients and patients on dialysis are at an increased risk of TB and poorer TB 
outcomes 29. One study in India reported a 4% incidence of TB, despite negative tuberculin skin 
tests (TST) in the majority 30. Similarly, a study of hemodialysis patients in Turkey also reported a 
3.1% incidence of TB with almost 40% of patients having a negative TST 31. This suggests that 
there should be a high index of suspicion of TB in these patients regardless of TST results. 
Examining factors associated with treatment non-adherence or death, a study in Brazil found that 
socio-demographic characteristics such as younger age and alcoholism were associated with 
poorer outcomes 32. 
The co-existence of TB also complicates management of blood pressure in CKD patients, as 
concurrent TB treatment is associated with a decrease in the potency of antihypertensive treatment 
33.  
B.4.1.4 Tuberculosis and the heart 
Tuberculosis is the most common cause of pericarditis in Africa and other high TB burden settings; 
often presenting with symptoms similar to those of heart failure 34. The increase in the burden of TB 
pericarditis has been attributed to HIV 35 and in the Western Cape, South Africa, 50% of patients 
with pericardial effusions are HIV-infected 36. Given these data, TB is an important consideration in 
persons presenting with heart failure in high TB burden settings; especially if HIV-infection is 
present. However, significant challenges remain, including diagnostic difficulty due to atypical 
presentation and varying evidence on the optimal management of these co-morbid conditions 35.  
B.4.2 HIV  
Globally, HIV is the 5th and 6th leading cause of DALYs lost and mortality, respectively 37,38. There 
are promising signs that the HIV pandemic is abating in high burden settings, with declining 
incidence and mortality rates 39. Nonetheless, the rising NCD morbidity and mortality rates 
alongside an established HIV epidemic make it crucial to better understand the interactions that 
exist with emerging NCD and disease precursors, both related to HIV directly or as a side effect of 
antiretroviral therapy (ART). LMIC bear a disproportionate burden of the HIV pandemic. 
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Furthermore, HIV-infected adults on treatment have higher than expected risk of several non-AIDS 
disorders, including cardiovascular disease and kidney disease in addition to adverse effects 
associated with ART 40,41. HIV has also been identified in a case control study as an independent 
risk factor for stroke in urban and rural Tanzania 42, although there is a paucity of data on the nature 
and extent of this interaction in LMIC. 
B.4.2.1 HIV and metabolic syndrome  
There is conflicting evidence on an association between HIV infection and hyperglycemia (including 
T2DM) independent of ART. 43,44. The use of ART containing protease inhibitors (PI) and 
nucleoside reverse transcriptase inhibitors has been associated with insulin resistance 45,46. A Cape 
Town survey of HIV-infected persons on ART reported a 21.9% prevalence of newly detected 
hyperglycemia and a significant association with efavirenz (a non-nucleoside reverse transcriptase 
inhibitor) 47. HIV-related dyslipidemia independent of ART has been described 48. The use of ART is 
also associated with dyslipidemia, peripheral wasting and central fat accumulation. In particular PI 
and non-nucleoside reverse transcriptase inhibitors (NNRTI)-based regimens have been 
associated with dyslipidemia and atrophy. PI drugs are particularly associated with dyslipidemia, a 
known risk factor for cardiovascular complications 49,50; patients with baseline elevated lipid levels 
have the greatest risk of developing dyslipidemia, especially hypertriglyceridemia 49. A study 
conducted in South Africa reported an association between ART and increased central fat and 
reduced peripheral fat; partially improved by switching from an NNRTI to a PI-based regimen 51.  
B.4.2.2 HIV and the heart 
The most commonly reported cardiac manifestation in HIV is pericardial disease; often due to TB 52. 
HIV-related dilated cardiomyopathy is also common with the prevalence in the pre-ART era ranging 
between 18-43% in LMIC 53,54. The prognosis of this condition has historically been poor 55,56, 
although the prevalence has decreased with the roll out of ART 52. Evidence from Africa on the 
prevalence of echocardiographic abnormalities in asymptomatic HIV-infected persons is limited 
although documented in other regions to vary from a 34-48% prevalence of systolic and diastolic 
dysfunction, and >10% prevalence of dilated cardiomyopathy 57,58. Pulmonary hypertension is also 
associated with HIV infection; with a prevalence of between 0.5-5% 52. Although mortality 
associated with pulmonary hypertension has significantly decreased post-ART roll out, specific 
treatment for pulmonary hypertension is required to improve cardiac function 59. There is an 
increased risk of myocardial infarction in HIV-infected patients on ART, particularly in patients with 
metabolic syndrome 60. PI drugs have been shown to be associated with a 26% increase in the rate 
of myocardial infarction per year of exposure, partially due to dyslipidemia 61. This was found with 
some (e.g. indinavir, ritonavir-boosted lopinavir) 62; but not others (boosted atazanavir) 63. Evidence 
on the CVD risk associated with nucleoside reverse transcriptase inhibitors is conflicting; however a 
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recent meta-analysis demonstrated no increased risk 64. There has been no proven association 
between T2DM and other ART drug classes. Drug-drug interactions are also important to mention 
due to interaction of ART with the cytochrome P450 pathway 52. 
B.4.2.3 HIV and Chronic Kidney Disease 
CKD is an important cause of morbidity and mortality in HIV-infected persons; including HIV-
associated nephropathy and membranoproliferative glomerulonephritis, particularly in hepatitis C 
co-infection 65. The risk of CKD is further increased in the presence of other risk factors including 
older age, hypertension, diabetes, and black ethnicity 66. Although the incidence of CKD has been 
remarkably altered by widespread ART access, some ART regimens are associated with incident 
acute or chronic kidney disease 67. Studies of HIV-infected patients on ART in Taiwan and Vietnam 
reported a 7% prevalence of CKD, with older age, lower body weight and tenofovir use being 
independently associated with CKD 68,69. However, the benefits of tenofovir are considered to 
outweigh the nephrotoxic side effects 70.  
B.4.2.4 HIV and Chronic Obstructive Pulmonary Disease  
Studies have shown an increased risk of Chronic Obstructive Pulmonary Disease (COPD) in HIV-
infected patients. Studies conducted in the pre-ART era demonstrated an association between HIV 
and airway hyper-responsiveness as well as radiographic emphysema 71,72. A post-ART era study 
conducted in the USA showed that after adjusting for known COPD risk factors, HIV remained an 
independent risk factor for COPD with HIV-infected patients 50-60% more likely to have COPD 
than HIV-negative 73. These findings have been confirmed in other studies conducted in the USA 
24,74 and Italy 75. A French study reported a 26% prevalence of COPD among HIV-infected persons, 
74% of which were previously undiagnosed 76. There is a paucity of data on HIV and COPD from 
high HIV prevalence LMIC. With increasing periods on ART, pulmonary complications are shifting 
from opportunistic infections to non-infectious complications such as COPD.  
B.4.2.5 HIV and the brain 
Neurocognitive disease and dementia 
We highlight 3 aspects of ageing in HIV: HIV patients are surviving for longer periods; an increasing 
proportion of incident HIV cases are in older persons who may perceive themselves to be at low 
risk of HIV; and HIV and ART are thought to be associated with acceleration of the ageing process 
such that illnesses associated with advanced age occur at younger ages 77. These combined 
processes mean that co-morbidity of neurocognitive disorders such as HIV associated 
neurocognitive disorder (HAND) will become increasingly more common. A study in Nigeria 
reported a 21.5% prevalence of HAND in HIV-infected patients on ART for at least 1 year 78.  
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Epilepsy and Seizures  
Seizures, a neurological manifestation of HIV infection, are mostly of the generalized type, and are 
more common in advanced stages of HIV, although they may rarely be the presenting 
manifestation or occur early in the course of illness 79. Reported causes include mass lesions, 
opportunistic infections including toxoplasmosis and cryptococcal meningitis and the direct effect of 
HIV on the brain (HIV encephalopathy) 79. The reported incidence of new-onset seizures vary from 
4-20% 79,80, with a higher prevalence in LMIC, likely due to a higher prevalence of opportunistic 
infections. The management of co-morbid HIV and epilepsy can be challenging. Phenytoin is the 
most commonly prescribed anti-epileptic drug and this drug induces the CYP450 system and can 
result in ART failure to control HIV viral replication 81 or phenytoin toxicity 82. This highlights the 
importance of careful monitoring of viral load and anti-epileptic drug levels; and careful selection of 
anti-epileptics such as levetiracetam 83. However, in many LMIC, choices of anti-epileptic drugs are 
limited.  
B.4.3 MALARIA 
B.4.3.1 Malaria and diabetes  
There is evidence from a recent case control study conducted in urban Ghana that people with 
T2DM are roughly 50% more likely to show evidence, based on testing for the DNA of the parasite, 
of infection with falciparum malaria 84. It is important to note that participants in this study did not 
have clinical malaria. However, the findings do support the hypothesis that people with T2DM may 
be at increased risk of clinical malaria.  
 
Clinical malaria in adults with T2DM is likely to be relatively common in endemic areas that also 
have a high prevalence of T2DM, such as many urban centers in Africa and Asia. However, there is 
a lack of evidence on whether people with T2DM who develop clinical malaria have poorer 
outcomes than people without T2DM.  
B.4.3.2 Malaria and Chronic kidney disease  
Chronic kidney disease and risk of malaria  
Chronic kidney disease (CKD) was ranked the 18th commonest cause of death globally in 2010, 
estimated to have caused 736,000 deaths 85. T2DM and hypertension are the two most important 
risk factors for CKD 85, and as these increase in LMIC, so will CKD.  The clinical end point of CKD 
is end stage kidney disease (ESKD), which can be defined by the requirement for life saving 
dialysis or renal transplantation 86. Worldwide it is estimated that 1.9 million people are undergoing 
some form of renal replacement therapy (RRT) 87. In LMIC, it is estimated that only around a 
quarter of those who require RRT receive it.  
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It is not known if CKD increases the risk of clinical malaria. It is known, however, that renal 
transplantation in malarial areas is associated with a risk of malaria in the recipients, the infection 
being transmitted via the donor kidney 88.Thus, it is recommended that renal transplant patients in 
malarial areas receive appropriate prophylaxis to eliminate the risk of this potentially life threatening 
complication 88.   
 
Finally, three of the drugs commonly used in malaria prophylaxis (malarone, proguanil and 
chloroquine) may be contraindicated in patients with CKD, depending on the level of renal 
impairment 89.  
 
Malaria as a cause of kidney disease 
One form of malaria, Plasmodium malariae, is associated with a risk of progressive renal damage 
(nephrotic syndrome) which even after successful eradication of the infection may progress to 
ESKD, and thus require RRT 88. This condition occurs predominantly in children and young adults. 
While it is a well-recognized condition, good estimates of its incidence and overall contribution to 
ESKD are lacking. It is thought to occur in only a fraction of Plasmodium malariae infections but it is 
described as one of the major causes of renal disease in children living in malarial areas 90.  
 
It is estimated that falciparum malaria is associated with acute renal failure in 1 to 5% of cases 
occurring in local inhabitants in endemic areas, but that in non-immune visitors around a quarter 
suffer this complication 88. Successful treatment of the infection normally leads to recovery of renal 
function within 2 to 6 weeks. However, during the acute phase many patients (40 to 70%) require 
dialysis 88.  
B.5 DISCUSSION OF IMPLICATIONS FOR HEALTH SYSTEMS  
This review highlights the complex interactions between established communicable and emerging 
non-communicable diseases in LMIC. The results emphasise the importance of re-thinking disease 
classifications in the context of disease prevention, promotion, treatment and care.  
 
The increasing prevalence of communicable / NCD multimorbidity in many LMIC settings, 
particularly in socio-economically disadvantaged groups suggests that this changing pattern of 
disease has significant implications for the health system and models of health care delivery. For 
example, a recent study in a peri-urban informal township near Cape Town, South Africa showed 
that 19% of HIV-infected patients on ART were on treatment for another chronic disease; with 77% 
and 17% of these patients concurrently receiving anti-hypertensive and diabetic treatment 
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respectively 91. There is therefore a need to ensure integrated care across the continuum of care 
from primary to tertiary levels.  
 
The Innovative Care for Chronic Conditions (ICCC) Framework developed by the World Health 
Organization addresses the increasing burden of chronic diseases in LMIC and is a tool designed 
to assist health systems to shift from providing predominantly acute episodic care in order to meet 
the increasing needs of chronic disease care 92. However, it does not explicitly incorporate the 
concept of co-existing and interacting multiple morbidities in these settings. A conceptual 
modification to this framework has been proposed that incorporates these multiple morbidities and 
examines the impact beyond biological interaction of these diseases 93. This modified framework 
could be used as a tool to help guide the development of integrated interventions at multiple levels. 
Models for integration of commonly occurring conditions need to be evaluated to optimize and 
streamline management. Integrated Chronic Disease Models are being developed and 
implemented in some LMIC. An example is the Integrated Chronic Disease Management model in 
South Africa that includes HIV, TB, diabetes, hypertension, asthma, epilepsy, asthma, chronic 
obstructive pulmonary disease and mental health illnesses. This model builds of the strengths of 
the HIV/TB integrated programme and focuses on a systems approach to re-structuring the primary 
health care system; improving efficiency using integrated clinical algorithms, clinic stationery and 
re-organised clinic flows as well the integrated training of community care workers in the 
prevention, promotion and treatment of these diseases. In the context of multimorbidity, the model 
also aims to empower patients and assist with self-management of their chronic diseases. 
Integration of community support groups is another approach to supporting patients with multiple 
and interacting chronic diseases potentially improving adherence to treatment and disease 
outcomes. 
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Figure B.2: Life-course approach to joint communicable and NCD prevention and control 
 
When considering interventions aimed at primary prevention, Figure 2 highlights the importance, 
both of considering shared risk factors (identified in Figure 1) that influence the risk and outcomes, 
and of using a life course approach when considering targets for intervention. Women have a 
disproportionally higher prevalence of certain NCD risk factors, particularly obesity and lower 
physical activity and in addition show rising rates of smoking and alcohol consumption 94. Given this 
fact, along with the impact of maternal factors on fetal and child health; and the likelihood of 
strongly influencing dietary household choices, female adolescents and adults represent an 
important population group for intervention. These interventions should ideally occur pre-conception 
and cover nutrition, physical activity, contraception, high-risk behavior including high-risk sexual 
practices, smoking and alcohol consumption. Figure 2 also highlights the importance of focusing on 
the elderly as ageing is associated with increasing prevalence of NCD and an increased 
susceptibility to communicable diseases. With increasing access to ART, there is increasing 
survival and ageing in HIV-infected persons. However, public health HIV control interventions often 
ignore this age group. Furthermore, immunocompromise associated with ageing increases the risk 
of other communicable diseases including TB, potentially compounded by the increased risk of 
T2DM. Given the high prevalence of NCD, older persons in LMIC are at a high risk of developing 
multi-morbid communicable and non-communicable conditions 95. This can result in disability, 
reduced quality of life, and social isolation, limiting their ability to fulfill emotional, cultural and 
economic roles within families and the society. Interventions that address isolation and promote 
social participation have been identified as potentially important in the elderly 96. 
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B.6 CONCLUSION 
The aim of this review was to illustrate the overlap and interaction between communicable and 
NCD, particularly in LMIC, and show how the agendas for their prevention and control are 
inextricably linked. There is therefore a need for those responsible for the design of health systems 
within individual countries to understand the distribution and interaction of communicable and NCD 
within their own populations in order to appropriately plan preventive and treatment programs and 
services. When it comes to the provision of health care for treatment this will require breaking down 
barriers between departments within health ministries that have traditionally designed services and 
programs for communicable and NCD separately. When it comes to prevention, it will require 
integrated multi-sectoral action addressing determinants across the life course.  
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C.1 ABSTRACT 
BACKGROUND 
Many low and middle-income countries are experiencing colliding epidemics of chronic infectious 
(ID) and non-communicable diseases (NCD). As a result, the prevalence of multiple morbidities 
(MM) is rising. 
METHODS 
We conducted a retrospective cohort study to describe the epidemiology of MM in a primary care 
clinic in Khayelitsha. Adults with at least one of HIV, tuberculosis (TB), diabetes (T2DM), and 
hypertension (HPT) were identified between Sept 2012-May 2013 on electronic databases. Using 
unique patient identifiers, drugs prescribed across all facilities in the province were linked to each 
patient and each drug class assigned a condition. 
RESULTS 
These 4 diseases accounted for 45% of all prescription visits. Among 14364 chronic disease 
patients, HPT was the most common morbidity (65%). 22.6% of patients had MM, with an 
increasing prevalence with age, and a high prevalence among younger antiretroviral therapy (ART) 
patients (26% in 18-35yr and 30% in 36-45 year age groups). HPT and T2DM prevalence was 
higher among younger patients on ART with MM compared to those not on ART. Of note, 37% of 
TB MM patients were also on treatment for HPT and 12% on treatment for T2DM, and 86% of 
T2DM patients were on HPT treatment.  
 
CONCLUSION 
We highlight the co-existence of multiple ID and NCD. This presents both challenges (increasing 
complexity and the impact on health services, providers and patients), and opportunities for chronic 
diseases screening in a population linked to care. It also necessitates re-thinking of models of health 
care delivery and calls for policy interventions that integrate and coordinate management of co-
morbid chronic diseases.  
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C.2 INTRODUCTION  
The concept of multi-morbidity (MM), defined as the co-existence of more than one chronic 
condition in one person, is well recognized, usually within the context of older age [1]. Patients with 
MM have increased utilization of health care, a reduced quality of life and poorer health outcomes 
[2-4]. A recent systematic review of MM patterns described a non-random pattern of MM for which 
common pathophysiological mechanisms underlie each disease constellation [1]. However all 
studies in this review were conducted in high-income settings, predominantly in older age 
populations, and included only non-communicable diseases (NCD). In low- and middle-income 
countries (LMIC), with burgeoning urbanisation, not only is the prevalence of NCD increasing, it is 
occurring alongside chronic infectious diseases.  
South Africa is the most urbanised country in sub-Saharan Africa with 62% of the country’s 
population living in cities [1, 5]. The rapid and unplanned nature of this demographic shift affects 
life choices and opportunities; contributing to epidemiological transition with an increase in 
unhealthy dietary patterns, a decrease in physical activity and a rising NCD burden [2-4, 6, 7]. South 
Africa has the highest burden of hypertension (HPT) in the >50years old population and among the 
highest type 2 diabetes mellitus (T2DM) prevalence in sub-Saharan Africa [1, 8, 9]; this is predicted 
to increase further over the next few decades. Against this background, the burden of HIV and 
tuberculosis (TB) remain high. Effective antiretroviral therapy (ART), in widespread use in South 
Africa since 2005/6, has resulted in increasing survival and ageing among HIV-infected persons and 
an accompanying rise in NCD co-morbidities in this sub-group [10, 11]. Furthermore, the premature 
ageing effect of HIV will likely further contribute to multiple morbidities in the population [12], at 
younger ages than described in low HIV-burden settings. The morbidity and mortality rates for 
NCD, HIV and TB in South Africa disproportionately affects poor people with the NCD burden 
fuelled by a high prevalence of obesity, which affects 40% of the adult female population [7]. 
A better understanding of the patterns of chronic infectious and non-communicable disease MM in 
LMIC is therefore required to develop strategies to prevent and better manage these co-existing and 
interacting conditions. A study conducted in the UK comparing measures of MM found the number 
of prescribed drugs to be the most powerful measure for predicting future healthcare utilization and 
second most powerful for predicting mortality [13]. We aimed to use routine data from a public 
health programme to explore the distribution of chronic diseases and patterns of HIV, TB, and NCD 
MM in adults who have received care and treatment in a public clinic.  
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C.3 METHODS 
C.3.1 Study setting  
We conducted a retrospective study in Michael Mapongwana clinic, a primary care health facility in 
Khayelitsha, an informal township in Cape Town with a population of >500 000 predominantly 
black Africans. This study was approved by the University of Cape Town, Faculty of Health 
Sciences Human Research Ethics committee (HREC Ref no: 493/2014). 
C.3.2 Data sources 
Data on treatment prescriptions were extracted from two routine electronic databases. Patients who 
are considered stable on chronic disease medication receive their monthly prescriptions through the 
Chronic Disease Dispensing unit (CDU), an outsourced centralised unit that collects prescriptions 
for stable chronic patients from health facilities, dispenses the medicines, and returns them to the 
facilities which the patients attend, packaged in tamper-proof parcels. A record of medicines 
dispensed is kept on a database that is sent to the Western Cape Department of Health Data 
Repository on a monthly basis. The second database used is the electronic prescription system that 
manages pharmacy prescriptions electronically. This system has been in use across secondary and 
tertiary-level hospitals in the Western Cape province for >10 years and enables pharmacy records 
linked to an individual patient to be accessible across hospitals. Roll out of this system in primary 
care clinics began in September 2012 in Michael Mapongwana clinic in Khayelitsha. This database 
captures chronic disease patients not receiving medicines through the CDU, including sub-optimally 
managed chronic disease patients. Every patient accessing health care in the public clinics and 
hospitals is ascribed a unique patient master index (PMI) that serves to longitudinally link 
prescriptions across different databases and health care facilities. 
C.3.3 Population and sampling strategy 
Persons prescribed medicines for at least one of the four most prevalent chronic diseases (HIV, TB, 
T2DM, HPT) were identified from the electronic pharmacy and CDU databases from September 
2012, when the electronic pharmacy database was launched, to May 2013. This time period was 
selected to capture 6-monthly prescriptions over a 9-month period from the electronic pharmacy 
database. The anonymised dataset extracted included age, sex, and medications prescribed at all 
consultations over the study period. Using the PMI, medicines prescribed across all health facilities 
in the province were linked to each patient. Each drug class was assigned a condition based on 
South African prescription guidelines: HPT defined as a prescription of at least one of 
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hydrochlorthiazide, enalapril, or amlodipine; T2DM defined as a prescription of metformin, 
gliclazide, glibenclamide, or insulin; HIV/ART defined as prescription of ART; TB defined as 
prescription of rifampicin, isoniazid, or pyrazinamide. MM was defined as receiving medication for 
two or more of the 4 morbidities measured.  
C.3.4 Statistical analysis 
Descriptive analyses were represented using percentages, frequencies, and tabulation. Age 
categories 18-35, 36-45, 46-55, >55 were used to explore the age-distribution of chronic diseases 
and MM; stratified by sex using the λ2 test. The prevalence of MM was also calculated stratified by 
HIV/ART status, into ART and non-ART (HIV status unknown) groups, across the different age 
groups. Co-morbidity patterns across the individual chronic diseases were examined. The λ2 test was 
used to measure differences in the prevalence of chronic diseases and MM. The Shapiro-Wilk test 
was used to test for normality and the Kruskal Wallis test used to test for statistical significance of 
non-parametric continuous variables. Significance testing was done using 2-sided p-values and 95% 
confidence intervals. All data were analysed using STATA 12.0 (StataCorp, College Station, TX, 
USA). 
Role of funding sources: The funders had no role in the design, collection, analysis, and writing of 
this manuscript. TO confirms that she had full access to all data and had final responsibility for the 
decision to submit the manuscript for publication. 
C.4 RESULTS 
C.4.1 Baseline characteristics and descriptive analysis 
A total of 32 474 patients attended the clinic and received at least one prescription between 
September 2012 and May 2013. Of these, 14 700 (45%) were consultations for HIV, TB, T2DM or 
HPT. Three hundred and thirty six of the 14 700 patients were aged <18 years and excluded from 
further analysis. The final study population sample size was 14 364 adults. The age/sex distribution 
of the study population showed that while 71% of the total population were female, the male: female 
ratio increased with increasing age (Table C.1) with a higher proportion of male: female ratio in the 
46-55 and >55 years age groups. The median age was 46 years (interquartile range (IQR) 36-56) 
overall; 46 years (IQR 35-55) in females and 48 years (IQR 39-57) in males. The prevalence of 
HPT, T2DM, HIV and TB in the study population, overall and stratified by gender is summarized in 
Table C.1. As shown in Figure C.1 there was an increase in the prevalence of NCD (HPT and 
T2DM) with increasing age. Overall, the prevalence of HPT, T2DM and TB was higher in male 
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versus female participants. However, analysed by gender, it was evident that younger females had a 
higher prevalence of T2DM (18-35 age group; 7.5% vs. 5.8%, p=0.015) and HPT (26-35 (9.2% vs. 
8.5%, p<0.0001), 36-45 (18.7% vs. 16.8%, p<0.0001), and 46-55 (34.6% vs. 31.2%, p<0.0001) age 
groups). Men >55 had a higher prevalence of HPT (43.5% vs. 37.5%, p<0.001) and HIV/ART 
(8.1% vs. 3.2%, p<0.0001).  
 
Table C.1: Baseline characteristics of patients with prescriptions for at least one of HPT, T2DM, 
HIV/ART, and TB, overall and stratified by gender. *Gender assignment missing for 
14 patients. 
  Female % 
N=10231 
(95% C.I.)  
Male % 
N=4119 
(95% C.I.) 
Total % 
N=14350* 
(95% C.I.) 
Age 18-35 24.4 (23.5-25.2) 14.0 (12.9-15.1) 21.4 (20.7-22.1) 
 36-45 24.8 (23.9-25.6) 26.6 (25.3-28) 25.3 (24.6-26.0) 
 46-55 26.1 (25.3-27.0) 28.4 (27.1-29.8) 26.8 (26.1-27.5) 
 >55 24.7 (24.0-25.7) 31.0 (29.6-32.4) 26.6 (25.9-27.3) 
 Total N=10231 N=4119  
 Median age 
years (IQR) 
46 (35-55) 48 (39-57) 46 (36-56) 
HPT  63.9 (63.0-64.9) 66.3 (64.8-67.7) 64.6 (63.8-65.4) 
T2DM  17.7 (17.0-18.5) 19.6 (18.4-20.8) 18.3 (17.6-18.9) 
HIV 
/ ART 
 39.5 (38.5-40.4) 35.7 (34.3-37.2) 38.4 (37.6-39.2) 
TB  2.3 (2.1-2.6) 3.7 (3.2-4.4) 2.7 (2.5-3.0) 
The distribution of TB and HIV/ART prevalence also differed by gender. Females in the 18-35 age 
group had a higher HIV/ART (48% vs. 22.8%, p<0.0001), and TB (46.6% vs. 31.8%, p<0.0001) 
prevalence compared to men. By contrast, male patients aged 36-45 and 46-55 had a higher 
prevalence of HIV/ART (45.1% vs. 35.4%, p=0.021; and 24% vs. 13.5%, p<0.0001, respectively) 
and TB (34.4% vs. 22.3%, p<0.0001; and 22.7% vs. 17.7%, p=0.004, respectively) compared to 
females (Figure C.1).  
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Figure C.1: Distribution of HPT, T2DM, HIV/ART, and TB, stratified by gender across age groups 
among patients with prescriptions for at least one of HPT, T2DM, HIV/ART, and TB. 
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C.4.2 Burden and distribution of multimorbidity 
The overall prevalence of MM was 22.6% (n=3246) with no significant difference between sexes. 
The prevalence of MM increased with increasing age. Among patients with MM, 94% had 2 
morbidities, the most common combination of which was HPT and T2DM (Figure C.2). Five 
percent had 3 conditions of which HPT, T2DM, and HIV were the most common combination. 
There was no significant difference in the proportion of MM patients with double, triple, or 
quadruple morbidities between sexes (data not shown). The overall age distributions were similar, 
with the highest prevalence in the 36-45 and 46-55 age groups, across these MM categories (data not 
shown).  Although the prevalence of MM was highest in T2DM patients (88.1%), the number of 
patients with MM was highest in HPT patients (32.3% of 9 277 patients) due to the high overall 
prevalence of HPT (65%) of the sample population. The co-morbidity pattern differed across the 4 
diseases (Figure C.3). Among T2DM MM patients, 97% had HPT as a co-morbidity, while 75% of 
HPT MM patients were on T2DM treatment. Among TB MM patients (81.1% of all TB patients), 
HIV/ART was the most common co-morbidity (followed by HPT and T2DM); while HIV/ART MM 
patients were most commonly receiving HPT treatment (Figure C.3).  
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Figure C.2: Patterns and distribution of single, double, triple and quadruple morbidities. 
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Figure C.3: Proportion of patients with multimorbidity among 32 474 patients who attended the 
clinic and received any prescription; and the distribution of chronic disease morbidities and 
multimorbidities among patients with prescriptions for at least one of HPT, T2DM, HIV/ART, and 
TB. 
C.4.3 Age-specific multimorbidity and the effect of HIV 
The prevalence of MM among younger HIV/ART patients in the 18-35 and 36-45 age groups was 
higher than in the comparison group (HIV-infected not on ART / HIV-status unknown). However, 
this was not the case in the >55 age group, where the pattern was reversed; although the prevalence 
of HIV/ART in this older age-group was low (Figure C.4). Stratified by sex, there was a difference 
in the age distribution of HIV/ART MM patients with a higher MM prevalence in the youngest age 
group in females versus male patients (Figure C.4; p=0.017). By contrast, the peak in MM for male 
ART patients occurred in the older 46-55 age group. Further investigation of the pattern of co-
morbid conditions in HIV/ART patients with MM versus MM patients not on ART (HIV status 
unknown) in the 18-35 years age category revealed a higher prevalence of HPT (19.7% (95% 
confidence interval (C.I.) 3.1-4.7%) vs. 3.8% (95% C.I. 17.2-22.6%)) and T2DM (12.3% (95% C.I. 
8.3-18.0%) vs. 3.8% (95% C.I. 3.0-4.6%)) in ART MM patients.  
 58 
 
 
 
Figure C.4: Distribution of non-HIV morbidities among MM patients (n=3246), stratified by sex and 
ART groups. Error bars show 95% confidence intervals. 
 
A similar pattern for HPT (30.2% (95% C.I. 27.2-33.45%) vs. 14.6% (95% C.I. 13.1-16.1%)) and 
T2DM (25.8% (95% C.I. 20.0-32.7%) vs. 14.3% (95% C.I. 12.9-15.9%)) was found among MM 
patients in the 36-45 years age category (Figure C.5). In the next age group, 46-55 years, T2DM co-
morbidity remained higher in HIV-infected persons on ART (43.8% (95% C.I. 36.7-51.2%)) than 
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the non ART group (32.8% (95% C.I. 30.9-34.8%)) but the prevalence of HPT co-morbidity did not 
differ between the two groups. 
 
 
Figure C.5: Distribution of HPT and T2DM across age groups comparing HIV/ART MM patients 
with MM to those not on ART (HIV status unknown). Error bars show 95% confidence intervals. 
C.5 DISCUSSION  
This study examined co-morbidity patterns in a cohort of patients receiving at least one prescription 
for one of 4 diseases over a 9-month period, and has a number of major findings. Firstly, a quartet of 
chronic diseases accounted for 45% of all consultations in a community health centre providing 
primary care services for people of low socioeconomic status in Cape Town. Secondly, we found a 
22.6% prevalence of MM among chronic disease patients and an associative pattern of MM, with 
HPT and T2DM often co-existing. Furthermore HPT was the most common co-morbidity in both 
HIV/ART and T2DM patients. Thirdly, we demonstrated that while HIV/ART was the most 
common co-morbidity among TB patients, 37% and 12% of multi-morbid TB patients were also on 
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treatment for HPT and T2DM respectively. Fourthly, we found a high prevalence of MM in younger 
patients on ART (26% in 18-35 year and 30% in 36-45 year age groups). Lastly, we showed that 
among these younger HIV/ART patients with MM, HPT and T2DM prevalence was significantly 
higher than patients in the same age groups who were not on ART. 
 
Our results reveal a very high prevalence of HPT among chronic disease patients. This is congruent 
with national data that shows a high overall prevalence of HPT in the general population and that 
HPT is the commonest reason for attendance of primary health clinics in South Africa [14]. A 
national, population-based study of persons 50 years and older in South Africa reported HPT 
prevalence of 77.3% [15]. It is noteworthy that HPT was the most common co-morbidity in both 
T2DM and HIV/ART MM patients. It was not surprising that 88% of all T2DM MM patients were 
also on treatment for HPT; T2DM patients are routinely screened for HPT in this setting. On the 
other hand, blood pressure screening is not currently routine in the management of HIV/ART and 
TB patients. Further the finding that 75% of HPT patients with MM were on treatment for T2DM 
suggesting that HPT patients should also routinely be screened for T2DM, which is not current local 
practice. Our results are comparable to data from high-income settings. A recent study from Ireland 
examined co-morbidity patterns (including hypertension, heart disease, arthritis, depression, and 
chronic lung disease) and reported that 90% of a cohort of T2DM patients had another morbidity 
and 66% had HPT [16]. However, 90% of study participants in this study were >50 years old and 
HIV status was not documented.  
 
Among TB patients with other chronic disease co-morbidities, the prevalence of HIV co-infection 
was high. This was an expected result as the HIV/TB co-infection rate in this local setting has 
previously been estimated as 67% [17]. Our data demonstrated that in addition to HIV, TB patients 
also have a significant prevalence of HPT and T2DM. While these conditions may co-exist, some 
interact, through either shared risk factors or pathophysiology; or one disease influencing 
susceptibility and outcomes of the other. For example, T2DM is associated with a 2-3 fold higher 
risk of TB [18]. Further research is therefore required to evaluate the proportion of TB cases 
attributable to T2DM in this high HIV/TB/T2DM setting. 
MM was lower overall in HIV/ART patients compared to patients not on ART with unknown HIV 
status. However when stratified by age, we noted that in the younger age groups (18-35 and 36-45 
years), MM was higher in HIV/ART patients, in particular, there was a higher prevalence of HPT, 
T2DM and TB. One possible reason for this difference is the previously reported association 
between HIV/ART and premature and accelerated ageing [19]. This could also be due to increased 
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awareness of NCD among HIV/ART patients, and possibly increased access to NCD screening in 
ART clinics. Obesity in HIV-infected patients is an emerging issue in South Africa; with some 
antiretroviral drugs, such as non-nucleoside reverse transcriptase inhibitors currently in use in South 
Africa, contributing to lipodystrophy and truncal obesity, increasing the risk of T2DM, HPT, and 
metabolic syndrome [10, 20]. A study of MM in HIV-infected patients in the United States found a 
prevalence of MM of 65%, with prevalence increasing with increasing body mass index (BMI) [21]. 
In the 46-55 age group, while HPT prevalence was similar between groups, T2DM prevalence was 
higher in the HIV/ART group; possibly highlighting a previously reported association between an 
increased risk of dysglycaemia in HIV-infected patients on ART [20]. 
 
Multimorbidity results in complex disease patterns that may have multiplicative, and not merely 
additive, consequences on health outcomes; and could diminish patients’ ability to manage their 
condition and enact behavior changes that may be required to improve health. This increasing 
complexity impacts on both health services, through more intensive health care requirements, and on 
health providers, with an increased requirement for integrated generalist care at the primary care 
level. This changing pattern of disease will therefore require health policy and interventions that 
differ from traditional vertical approaches and single disease management such as integrated 
management of chronic disease patients considered to be stable [22]. Furthermore the associative 
patterns of MM described in this study suggest active bidirectional and targeted screening for these 
conditions should be implemented. Routine active screening is likely to result in an even higher 
burden of diagnosed co-morbidities in the short term, but diagnosis and intervention at an earlier 
stage may ultimately result in reduced overall cost. The impact of active screening on the health care 
system should therefore be evaluated. Beyond these direct interactions, MM and the associated 
increased complexity could also influence the psychological state or patients’ beliefs and values, 
influencing decision-making and acceptability of treatment options, and adherence to treatment [23]. 
C.5.1 Strengths and limitations 
A significant strength of this study is the use of the unique patient identifier number which enabled 
any treatment prescribed within the public health system in the Western Cape province, even if 
outside the primary care clinic, to be identified and included in the study. The availability of linked 
records in a public sector primary care setting is rare both within South Africa and sub-Saharan 
Africa. A limitation of this study is that it utilized data from routine databases of prescribed drugs. 
Diagnoses could therefore not be verified. As a result, only patients with diagnosed chronic diseases 
receiving treatment for the selected diseases were identified and included in this study. This could 
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underestimate the prevalence of the individual conditions and MM. Patients in chronic care for 
ART, HPT and T2DM are plausibly more likely than TB patients to have blood pressure and urine 
glucose measured over time due to regular clinic visits where routine observations may include 
these measurements; while HIV testing is routinely performed in TB but this is not HPT and T2DM 
clinics. Therefore ascertainment bias, with the potential for under ascertainment of NCD among TB 
patients, could be a factor. Similarly, in the context of high HIV prevalence in this setting, as 
emphasized in the methodology, it is important to interpret the HIV stratification within the context 
of ART versus non-ART as the ‘non-ART/HIV unknown’ subset are likely to include HIV-infected 
patients who have not been diagnosed, and those who have been diagnosed but who are not on ART. 
Another potential limitation was the use of prescribed drugs as a proxy for diagnosis. Whilst 
medications for T2DM, HIV, and TB are relatively specific to these diseases, the prescription of 
hydrochlorthiazide, enalapril or amlodipine may be prescribed for cardiovascular diseases and may 
not be specific to HPT. However, given the high prevalence of HPT of all chronic diagnoses in 
primary care [14], and the prescription patterns of doctors at the primary care level, we are confident 
that this proxy is a valid estimate of HPT. Prior to this study, to confirm prescription patterns in a 
primary care setting, we conducted a folder review of 100 patients attending another primary care 
clinic in Khayelitsha and found that these 3 drugs accounted for all HPT patients reviewed.  
From a health system perspective, despite these limitations, this study highlights the significant 
burden of MM among patients receiving chronic disease care at the primary health care level. 
C.6 CONCLUSION  
We demonstrated a high prevalence of chronic infectious and non-communicable diseases 
confirming the epidemiological transition in this peri-urban informal township in South Africa. This 
study significantly contributes to knowledge about the complex interdependencies in multimorbid 
diseases in South Africa, a middle-income country. The patterns of MM shown suggest that current 
models of health care delivery need to be re-examined and patient-centred models of integration 
evaluated including bidirectional screening of commonly co-morbid conditions in routine clinical 
practice. Furthermore, research into possible causal underlying mechanisms where unknown; and 
the implications for diagnosis and treatment, adherence, health outcomes, and capacity for behavior 
change is required.  
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D.2 BMC MEDICINE AUTHOR GUIDELINES 
Instructions for authors 
Guidelines 
Submission process | Preparing main manuscript text | Preparing illustrations and figures |Preparing 
tables | Preparing additional files | Style and language 
See 'About this journal' for descriptions of different article types and information about policies and 
the refereeing process. 
Guideline articles are similar to Research articles, but focus on providing evidence-based 
recommendations that will influence clinical research and practice. These can be consensus-based 
statements of reporting standards or clinical practice guidelines. 
Submission process 
Manuscripts must be submitted by one of the authors of the manuscript, and should not be submitted 
by anyone on their behalf. The submitting author takes responsibility for the article during 
submission and peer review. 
Please note that BMC Medicine levies an article-processing charge on all accepted Guidelines ; if the 
submitting author's institution is a BioMed Central member the cost of the article-processing charge 
may be covered by the membership (see About page for detail). Please note that the membership is 
only automatically recognised on submission if the submitting author is based at the member 
institution. 
To facilitate rapid publication and to minimize administrative costs, BMC Medicine prefers online 
submission. 
Files can be submitted as a batch, or one by one. The submission process can be interrupted at any 
time; when users return to the site, they can carry on where they left off. 
See below for examples of word processor and graphics file formats that can be accepted for the 
main manuscript document by the online submission system. Additional files of any type, such 
as movies, animations, or original data files, can also be submitted as part of the manuscript. 
During submission you will be asked to provide a cover letter. Use this to explain why your 
manuscript should be published in the journal, to elaborate on any issues relating to our editorial 
policies in the'About BMC Medicine' page, and to declare any potential competing interests. You 
will be also asked to provide the contact details (including email addresses) of potential peer 
reviewers for your manuscript. These should be experts in their field, who will be able to provide an 
objective assessment of the manuscript. Any suggested peer reviewers should not have published 
with any of the authors of the manuscript within the past five years, should not be current 
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collaborators, and should not be members of the same research institution. Suggested reviewers will 
be considered alongside potential reviewers recommended by the editorial team and/or by Editorial 
Board members or other advisers. 
Assistance with the process of manuscript preparation and submission is available from BioMed 
Central customer support team. 
We also provide a collection of links to useful tools and resources for scientific authors on 
our Useful Tools page. 
File formats 
The following word processor file formats are acceptable for the main manuscript document: 
Microsoft word (DOC, DOCX) 
Rich text format (RTF) 
Portable document format (PDF) 
TeX/LaTeX (use BioMed Central's TeX template) 
DeVice Independent format (DVI) 
TeX/LaTeX users: Please use BioMed Central's TeX template and BibTeX stylefile if you use TeX 
format. During the TeX submission process, please submit your TeX file as the main manuscript file 
and your bib/bbl file as a dependent file. Please also convert your TeX file into a PDF and submit 
this PDF as an additional file with the name 'Reference PDF'. This PDF will be used by internal staff 
as a reference point to check the layout of the article as the author intended. Please also note that all 
figures must be coded at the end of the TeX file and not inline. 
If you have used another template for your manuscript, or if you do not wish to use BibTeX, then 
please submit your manuscript as a DVI file. We do not recommend converting to RTF. 
For all TeX submissions, all relevant editable source must be submitted during the submission 
process. Failing to submit these source files will cause unnecessary delays in the publication 
procedures. 
Publishing Datasets 
Through a special arrangement with LabArchives, LLC, authors submitting manuscripts to BMC 
Medicine can obtain a complimentary subscription to LabArchives with an allotment of 100MB of 
storage. LabArchives is an Electronic Laboratory Notebook which will enable scientists to share and 
publish data files in situ; you can then link your paper to these data. Data files linked to published 
articles are assigned digital object identifiers (DOIs) and will remain available in perpetuity. Use of 
LabArchives or similar data publishing services does not replace preexisting data deposition 
requirements, such as for nucleic acid sequences, protein sequences and atomic coordinates. 
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Instructions on assigning DOIs to datasets, so they can be permanently linked to publications, can be 
found on the LabArchives website. Use of LabArchives’ software has no influence on the editorial 
decision to accept or reject a manuscript. 
Authors linking datasets to their publications should include an Availability of supporting 
data section in their manuscript and cite the dataset in their reference list. 
Preparing main manuscript text 
General guidelines of the journal's style and language are given below. 
Overview of manuscript sections for Guidelines 
Manuscripts for Guidelines submitted to BMC Medicine should be divided into the following 
sections (in this order): 
Title page 
Abstract 
Keywords 
Background 
Methods 
Results and discussion 
Conclusions 
List of abbreviations used (if any) 
Competing interests 
Authors' contributions 
Authors' information 
Acknowledgements 
Endnotes 
References 
Illustrations and figures (if any) 
Tables and captions 
Preparing additional files 
The Accession Numbers of any nucleic acid sequences, protein sequences or atomic coordinates 
cited in the manuscript should be provided, in square brackets and include the corresponding 
database name; for example, [EMBL:AB026295, EMBL:AC137000, DDBJ:AE000812, 
GenBank:U49845, PDB:1BFM, Swiss-Prot:Q96KQ7, PIR:S66116]. 
The databases for which we can provide direct links are: EMBL Nucleotide Sequence Database 
(EMBL), DNA Data Bank of Japan (DDBJ), GenBank at the NCBI (GenBank), Protein Data Bank 
(PDB), Protein Information Resource (PIR) and the Swiss-Prot Protein Database (Swiss-Prot). 
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You can download a template (Mac and Windows compatible; Microsoft Word 98/2000) for your 
article. 
For reporting standards please see the information in the About section. 
Title page 
The title page should: 
provide the title of the article 
list the full names, institutional addresses and email addresses for all authors 
indicate the corresponding author 
Please note: 
the title should include the study design, for example "A versus B in the treatment of C: a 
randomized controlled trial X is a risk factor for Y: a case control study" 
abbreviations within the title should be avoided 
Abstract 
The Abstract of the manuscript should not exceed 350 words and must be structured into separate 
sections: Background, the context and purpose of the study; Methods, how the study was 
performed and statistical tests used; Results, the main findings; Conclusions, brief summary and 
potential implications. Please minimize the use of abbreviations and do not cite references in the 
abstract. Trial registration, if your guideline reports the results of a controlled health care 
intervention, please list your trial registry, along with the unique identifying number (e.g. Trial 
registration: Current Controlled Trials ISRCTN73824458). Please note that there should be no 
space between the letters and numbers of your trial registration number. We recommend 
manuscripts that report randomized controlled trials follow the CONSORT extension for abstracts. 
Keywords 
Three to ten keywords representing the main content of the article. 
Background 
The Background section should be written in a way that is accessible to researchers without 
specialist knowledge in that area and must clearly state - and, if helpful, illustrate - the background 
to the research and its aims. Reports of clinical research should, where appropriate, include a 
summary of a search of the literature to indicate why this study was necessary and what it aimed to 
contribute to the field. The section should end with a brief statement of what is being reported in the 
article. 
Methods 
The methods section should include the design of the study, the setting, the type of participants or 
materials involved, a clear description of all interventions and comparisons, and the type of analysis 
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used, including a power calculation if appropriate. Generic drug names should generally be used. 
When proprietary brands are used in research, include the brand names in parentheses in the 
Methods section. 
For studies involving human participants a statement detailing ethical approval and consent should 
be included in the methods section. For further details of the journal's editorial policies and ethical 
guidelines see 'About this journal'. 
For further details of the journal's data-release policy, see the policy section in 'About this journal'. 
Results and discussion 
The Results and discussion may be combined into a single section or presented separately. Results 
of statistical analysis should include, where appropriate, relative and absolute risks or risk 
reductions, and confidence intervals. The Results and discussion sections may also be broken into 
subsections with short, informative headings. 
Conclusions 
This should state clearly the main conclusions of the research and give a clear explanation of their 
importance and relevance. Summary illustrations may be included. 
List of abbreviations 
If abbreviations are used in the text they should be defined in the text at first use, and a list of 
abbreviations can be provided, which should precede the competing interests and authors' 
contributions. 
Competing interests 
A competing interest exists when your interpretation of data or presentation of information may be 
influenced by your personal or financial relationship with other people or organizations. Authors 
must disclose any financial competing interests; they should also reveal any non-financial 
competing interests that may cause them embarrassment were they to become public after the 
publication of the manuscript. 
Authors are required to complete a declaration of competing interests. All competing interests that 
are declared will be listed at the end of published articles. Where an author gives no competing 
interests, the listing will read 'The author(s) declare that they have no competing interests'. 
When completing your declaration, please consider the following questions: 
Financial competing interests 
In the past three years have you received reimbursements, fees, funding, or salary from an 
organization that may in any way gain or lose financially from the publication of this manuscript, 
either now or in the future? Is such an organization financing this manuscript (including the article-
processing charge)? If so, please specify. 
 72 
Do you hold any stocks or shares in an organization that may in any way gain or lose financially 
from the publication of this manuscript, either now or in the future? If so, please specify. 
Do you hold or are you currently applying for any patents relating to the content of the manuscript? 
Have you received reimbursements, fees, funding, or salary from an organization that holds or has 
applied for patents relating to the content of the manuscript? If so, please specify. 
Do you have any other financial competing interests? If so, please specify. 
Non-financial competing interests 
Are there any non-financial competing interests (political, personal, religious, ideological, academic, 
intellectual, commercial or any other) to declare in relation to this manuscript? If so, please specify. 
If you are unsure as to whether you, or one your co-authors, has a competing interest please discuss 
it with the editorial office. 
Authors' contributions 
In order to give appropriate credit to each author of a paper, the individual contributions of authors 
to the manuscript should be specified in this section. 
According to ICMJE guidelines, An 'author' is generally considered to be someone who has made 
substantive intellectual contributions to a published study. To qualify as an author one should 1) 
have made substantial contributions to conception and design, or acquisition of data, or analysis and 
interpretation of data; 2) have been involved in drafting the manuscript or revising it critically for 
important intellectual content; 3) have given final approval of the version to be published; and 4) 
agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy 
or integrity of any part of the work are appropriately investigated and resolved. Each author should 
have participated sufficiently in the work to take public responsibility for appropriate portions of the 
content. Acquisition of funding, collection of data, or general supervision of the research group, 
alone, does not justify authorship. 
We suggest the following kind of format (please use initials to refer to each author's contribution): 
AB carried out the molecular genetic studies, participated in the sequence alignment and drafted the 
manuscript. JY carried out the immunoassays. MT participated in the sequence alignment. ES 
participated in the design of the study and performed the statistical analysis. FG conceived of the 
study, and participated in its design and coordination and helped to draft the manuscript. All authors 
read and approved the final manuscript. 
All contributors who do not meet the criteria for authorship should be listed in an 
acknowledgements section. Examples of those who might be acknowledged include a person who 
provided purely technical help, writing assistance, or a department chair who provided only general 
support. 
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Authors' information 
You may choose to use this section to include any relevant information about the author(s) that may 
aid the reader's interpretation of the article, and understand the standpoint of the author(s). This may 
include details about the authors' qualifications, current positions they hold at institutions or 
societies, or any other relevant background information. Please refer to authors using their initials. 
Note this section should not be used to describe any competing interests. 
Acknowledgements 
Please acknowledge anyone who contributed towards the article by making substantial contributions 
to conception, design, acquisition of data, or analysis and interpretation of data, or who was 
involved in drafting the manuscript or revising it critically for important intellectual content, but 
who does not meet the criteria for authorship. Please also include the source(s) of funding for each 
author, and for the manuscript preparation. Authors must describe the role of the funding body, if 
any, in design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; 
and in the decision to submit the manuscript for publication. Please also acknowledge anyone who 
contributed materials essential for the study. If a language editor has made significant revision of the 
manuscript, we recommend that you acknowledge the editor by name, where possible. 
The role of a scientific (medical) writer must be included in the acknowledgements section, 
including their source(s) of funding. We suggest wording such as 'We thank Jane Doe who provided 
medical writing services on behalf of XYZ Pharmaceuticals Ltd.' 
Authors should obtain permission to acknowledge from all those mentioned in the 
Acknowledgements section. 
Endnotes 
Endnotes should be designated within the text using a superscript lowercase letter and all notes 
(along with their corresponding letter) should be included in the Endnotes section. Please format this 
section in a paragraph rather than a list. 
References 
All references, including URLs, must be numbered consecutively, in square brackets, in the order in 
which they are cited in the text, followed by any in tables or legends. Each reference must have an 
individual reference number.. If automatic numbering systems are used, the reference numbers must 
be finalized and the bibliography must be fully formatted before submission. 
Only articles, datasets, clinical trial registration records and abstracts that have been published or are 
in press, or are available through public e-print/preprint servers, may be cited; unpublished abstracts, 
unpublished data and personal communications should not be included in the reference list, but may 
be included in the text and referred to as "unpublished observations" or "personal communications" 
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giving the names of the involved researchers. Obtaining permission to quote personal 
communications and unpublished data from the cited colleagues is the responsibility of the author. 
Footnotes are not allowed, but endnotes are permitted. Journal abbreviations follow Index 
Medicus/MEDLINE. Citations in the reference list should include all named authors, up to the first 
30 before adding 'et al.'.. 
Any in press articles cited within the references and necessary for the reviewers' assessment of the 
manuscript should be made available if requested by the editorial office. 
Style files are available for use with popular bibliographic management software: 
BibTeX 
EndNote style file 
Reference Manager 
Zotero 
Examples of the BMC Medicine reference style are shown below. Please ensure that the reference 
style is followed precisely; if the references are not in the correct style they may have to be retyped 
and carefully proofread. 
All web links and URLs, including links to the authors' own websites, should be given a reference 
number and included in the reference list rather than within the text of the manuscript. They should 
be provided in full, including both the title of the site and the URL, in the following format: The 
Mouse Tumor Biology Database [http://tumor.informatics.jax.org/mtbwi/index.do]. If an author or 
group of authors can clearly be associated with a web link, such as for weblogs, then they should be 
included in the reference. 
Examples of the BMC Medicine reference style 
 
 
Article within a journal 
Koonin EV, Altschul SF, Bork P: BRCA1 protein products: functional motifs. Nat 
Genet 1996,13:266-267. 
Article within a journal supplement 
Orengo CA, Bray JE, Hubbard T, LoConte L, Sillitoe I: Analysis and assessment of ab initio 
three-dimensional prediction, secondary structure, and contacts 
prediction. Proteins 1999, 43(Suppl 3):149-170. 
In press article 
Kharitonov SA, Barnes PJ: Clinical aspects of exhaled nitric oxide. Eur Respir J, in press. 
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Published abstract 
Zvaifler NJ, Burger JA, Marinova-Mutafchieva L, Taylor P, Maini RN: Mesenchymal cells, 
stromal derived factor-1 and rheumatoid arthritis [abstract]. Arthritis Rheum 1999, 42:s250. 
Article within conference proceedings 
Jones X: Zeolites and synthetic mechanisms. In Proceedings of the First National Conference on 
Porous Sieves: 27-30 June 1996; Baltimore. Edited by Smith Y. Stoneham: Butterworth-
Heinemann; 1996:16-27. 
Book chapter, or article within a book 
Schnepf E: From prey via endosymbiont to plastids: comparative studies in 
dinoflagellates. InOrigins of Plastids. Volume 2. 2nd edition. Edited by Lewin RA. New York: 
Chapman and Hall; 1993:53-76. 
Whole issue of journal 
Ponder B, Johnston S, Chodosh L (Eds): Innovative oncology. In Breast Cancer Res 1998, 10:1-72. 
Whole conference proceedings 
Smith Y (Ed): Proceedings of the First National Conference on Porous Sieves: 27-30 June 1996; 
Baltimore. Stoneham: Butterworth-Heinemann; 1996. 
Complete book 
Margulis L: Origin of Eukaryotic Cells. New Haven: Yale University Press; 1970. 
Monograph or book in a series 
Hunninghake GW, Gadek JE: The alveolar macrophage. In Cultured Human Cells and 
Tissues. Edited by Harris TJR. New York: Academic Press; 1995:54-56. [Stoner G (Series 
Editor): Methods and Perspectives in Cell Biology, vol 1.] 
Book with institutional author 
Advisory Committee on Genetic Modification: Annual Report. London; 1999. 
PhD thesis 
Kohavi R: Wrappers for performance enhancement and oblivious decision graphs. PhD 
thesis.Stanford University, Computer Science Department; 1995. 
Link / URL 
The Mouse Tumor Biology Database [http://tumor.informatics.jax.org/mtbwi/index.do] 
Link / URL with author(s) 
Corpas M: The Crowdfunding Genome Project: a personal genomics community with open 
source values [http://blogs.biomedcentral.com/bmcblog/2012/07/16/the-crowdfunding-genome-
project-a-personal-genomics-community-with-open-source-values/] 
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Dataset with persistent identifier 
Zheng, L-Y; Guo, X-S; He, B; Sun, L-J; Peng, Y; Dong, S-S; Liu, T-F; Jiang, S; Ramachandran, S; 
Liu, C-M; Jing, H-C (2011): Genome data from sweet and grain sorghum (Sorghum 
bicolor).GigaScience Database. http://dx.doi.org/10.5524/100012. 
Clinical trial registration record with persistent identifier 
Mendelow, AD (2006): Surgical Trial in Lobar Intracerebral Haemorrhage. Current Controlled 
Trials. http://dx.doi.org/10.1186/ISRCTN22153967 
Preparing illustrations and figures 
Illustrations should be provided as separate files, not embedded in the text file. Each figure should 
include a single illustration and should fit on a single page in portrait format. If a figure consists of 
separate parts, it is important that a single composite illustration file be submitted which contains all 
parts of the figure. There is no charge for the use of color figures. 
Please read our figure preparation guidelines for detailed instructions on maximising the quality of 
yourfigures. 
Formats 
The following file formats can be accepted: 
PDF (preferred format for diagrams) 
DOCX/DOC (single page only) 
PPTX/PPT (single slide only) 
EPS 
PNG (preferred format for photos or images) 
TIFF 
JPEG 
BMP 
Figure legends 
The legends should be included in the main manuscript text file at the end of the document, rather 
than being a part of the figure file. For each figure, the following information should be provided: 
Figure number (in sequence, using Arabic numerals - i.e. Figure 1, 2, 3 etc); short title of figure 
(maximum 15 words); detailed legend, up to 300 words. 
Please note that it is the responsibility of the author(s) to obtain permission from the copyright 
holder to reproduce figures or tables that have previously been published elsewhere. 
Preparing a personal cover page 
If you wish to do so, you may submit an image which, in the event of publication, will be used to 
create a cover page for the PDF version of your article. The cover page will also display the journal 
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logo, article title and citation details. The image may either be a figure from your manuscript or 
another relevant image. You must have permission from the copyright to reproduce the image. 
Images that do not meet our requirements will not be used. 
Images must be 300dpi and 155mm square (1831 x 1831 pixels for a raster image). 
Allowable formats - EPS, PDF (for line drawings), PNG, TIFF (for photographs and screen dumps), 
JPEG, BMP, DOC, PPT, CDX, TGF (ISIS/Draw). 
Preparing tables 
Each table should be numbered and cited in sequence using Arabic numerals (i.e. Table 1, 2, 3 etc.). 
Tables should also have a title (above the table) that summarizes the whole table; it should be no 
longer than 15 words. Detailed legends may then follow, but they should be concise. Tables should 
always be cited in text in consecutive numerical order. 
Smaller tables considered to be integral to the manuscript can be pasted into the end of the document 
text file, in A4 portrait or landscape format. These will be typeset and displayed in the final 
published form of the article. Such tables should be formatted using the 'Table object' in a word 
processing program to ensure that columns of data are kept aligned when the file is sent 
electronically for review; this will not always be the case if columns are generated by simply using 
tabs to separate text. Columns and rows of data should be made visibly distinct by ensuring that the 
borders of each cell display as black lines. Commas should not be used to indicate numerical values. 
Color and shading may not be used; parts of the table can be highlighted using symbols or bold text, 
the meaning of which should be explained in a table legend. Tables should not be embedded as 
figures or spreadsheet files. 
Larger datasets or tables too wide for a portrait page can be uploaded separately as additional files. 
Additional files will not be displayed in the final, laid-out PDF of the article, but a link will be 
provided to the files as supplied by the author. 
Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls ) or comma 
separated values (.csv). As with all files, please use the standard file extensions. 
Preparing additional files 
Although BMC Medicine does not restrict the length and quantity of data included in an article, we 
encourage authors to provide datasets, tables, movies, or other information as additional files. 
Please note: All Additional files will be published along with the article. Do not include files such 
as patient consent forms, certificates of language editing, or revised versions of the main manuscript 
document with tracked changes. Such files should be sent by email 
tobmcmedicineeditorial@biomedcentral.com, quoting the Manuscript ID number. 
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Results that would otherwise be indicated as "data not shown" can and should be included as 
additional files. Since many weblinks and URLs rapidly become broken, BMC Medicine requires 
that supporting data are included as additional files, or deposited in a recognized repository. Please 
do not link to data on a personal/departmental website. The maximum file size for additional files is 
20 MB each, and files will be virus-scanned on submission. 
Additional files can be in any format, and will be downloadable from the final published article as 
supplied by the author. We recommend CSV rather than PDF for tabular data. 
Certain supported files formats are recognized and can be displayed to the user in the browser. 
These include most movie formats (for users with the Quicktime plugin), mini-websites prepared 
according to our guidelines, chemical structure files (MOL, PDB), geographic data files (KML). 
If additional material is provided, please list the following information in a separate section of the 
manuscript text: 
File name (e.g. Additional file 1) 
File format including the correct file extension for example .pdf, .xls, .txt, .pptx (including name and 
a URL of an appropriate viewer if format is unusual) 
Title of data 
Description of data 
Additional files should be named "Additional file 1" and so on and should be referenced explicitly 
by file name within the body of the article, e.g. 'An additional movie file shows this in more detail 
[see Additional file 1]'. 
Additional file formats 
Ideally, file formats for additional files should not be platform-specific, and should be viewable 
using free or widely available tools. The following are examples of suitable formats. 
Additional documentation 
PDF (Adode Acrobat) 
Animations 
SWF (Shockwave Flash) 
Movies 
MP4 (MPEG 4) 
MOV (Quicktime) 
Tabular data 
XLS, XLSX (Excel Spreadsheet) 
CSV (Comma separated values) 
As with figure files, files should be given the standard file extensions. 
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Mini-websites 
Small self-contained websites can be submitted as additional files, in such a way that they will be 
browsable from within the full text HTML version of the article. In order to do this, please follow 
these instructions: 
Create a folder containing a starting file called index.html (or index.htm) in the root. 
Put all files necessary for viewing the mini-website within the folder, or sub-folders. 
Ensure that all links are relative (ie "images/picture.jpg" rather than "/images/picture.jpg" or 
"http://yourdomain.net/images/picture.jpg" or "C:\Documents and Settings\username\My 
Documents\mini-website\images\picture.jpg") and no link is longer than 255 characters. 
Access the index.html file and browse around the mini-website, to ensure that the most commonly 
used browsers (Internet Explorer and Firefox) are able to view all parts of the mini-website without 
problems, it is ideal to check this on a different machine. 
Compress the folder into a ZIP, check the file size is under 20 MB, ensure that index.html is in the 
root of the ZIP, and that the file has .zip extension, then submit as an additional file with your 
article. 
Style and language 
General 
Currently, BMC Medicine can only accept manuscripts written in English. Spelling should be US 
English or British English, but not a mixture. 
There is no explicit limit on the length of articles submitted, but authors are encouraged to be 
concise. There is also no restriction on the number of figures, tables or additional files that can be 
included with each article online. Figures and tables should be numbered in the order in which they 
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